Erin D. Michos, MD, MHS

Articles by Erin D. Michos, MD, MHS

Lp(a) in Pediatrics

BySeth Baum, MD,Erin D. Michos, MD, MHS,Amy Peterson, MD,Yehuda Handelsman, MD,Lisa Maher, MD

December 11th 2024

Panelists discuss how early identification of lipid disorders through pediatric screening is crucial yet underutilized, highlighting current guidelines and practical strategies to improve screening implementation in clinical practice.

Pediatric Lipid Screening

BySeth Baum, MD,Erin D. Michos, MD, MHS,Amy Peterson, MD,Yehuda Handelsman, MD,Lisa Maher, MD

December 4th 2024

Panelists discuss how pediatric lipid screening remains underutilized despite current recommendations and explore practical strategies to increase screening rates and identify cardiovascular risk factors early in childhood.

Role of LDL-C in ASCVD

BySeth Baum, MD,Erin D. Michos, MD, MHS,Amy Peterson, MD,Yehuda Handelsman, MD,Lisa Maher, MD

December 4th 2024

Panelists discuss how elevated LDL-C levels significantly contribute to ASCVD development through both modifiable lifestyle factors and genetic predisposition, making it a critical target for cardiovascular disease prevention.

AHA Guidelines and Patient Mortality

BySeth Baum, MD,Erin D. Michos, MD, MHS,Amy Peterson, MD,Yehuda Handelsman, MD,Lisa Maher, MD

November 27th 2024

Panelists discuss how effective management of dyslipidemia through adherence to AHA guidelines is crucial for reducing cardiovascular mortality rates and improving patient outcomes.

Prevalence of Cardiovascular Disease

BySeth Baum, MD,Erin D. Michos, MD, MHS,Amy Peterson, MD,Yehuda Handelsman, MD,Lisa Maher, MD

November 27th 2024

Panelists discuss how cardiovascular disease remains a leading health concern in the United States, examining its rising prevalence, risk factors such as dyslipidemia, and management strategies aligned with AHA guidelines to reduce patient mortality.

Cardiometabolic Medicine: Seeing the Patient as a Whole

ByPam Taub, MD, FACC, FASPC,Michael Koren, MD, FACC ,Erin D. Michos, MD, MHS,Michael Blaha, MD,Deepak Bhatt, MD, MPH, MBA

June 12th 2024

The panelists stress the significance of a comprehensive approach to patient care, acknowledging the interconnected nature of cardiovascular, kidney, endocrine, and obesity-related benefits, and highlighting that addressing secondary diseases can minimize overall disease risk in patients.

Overcoming Prior Authorization Barriers in LDL Cholesterol Therapies

ByPam Taub, MD, FACC, FASPC,Michael Koren, MD, FACC ,Erin D. Michos, MD, MHS,Michael Blaha, MD,Deepak Bhatt, MD, MPH, MBA

June 5th 2024

Michael Koren, MD addresses the challenges posed by prior authorization and the diminished role of pharmaceutical sales representatives in informing providers about medication advancements, leading to a disconnect in the provider's treatment arsenal.

Medication Adherence in Patients with High LDL Cholesterol

ByPam Taub, MD, FACC, FASPC,Michael Koren, MD, FACC ,Erin D. Michos, MD, MHS,Michael Blaha, MD,Deepak Bhatt, MD, MPH, MBA

June 5th 2024

The panel explores issues surrounding medication adherence and the potential for improved patient engagement. They emphasize that poor medication adherence increases the risk of cardiovascular events and discuss factors such as drug cost, timing of administration, and the importance of adopting a patient-centric approach to optimize treatment success.

Diabetes, GLP-1, and Lipid Reduction

ByPam Taub, MD, FACC, FASPC,Michael Koren, MD, FACC ,Erin D. Michos, MD, MHS,Michael Blaha, MD,Deepak Bhatt, MD, MPH, MBA

May 29th 2024

Michael Blaha, MD, highlights the potential of GLP-1 agonists in lowering LDL cholesterol, triglycerides, and body weight in patients with diabetes, presenting them as an additional option for reducing cardiovascular risk in this patient population.

REDUCE-IT Trial and Triglyceride-Lowering Agents

ByPam Taub, MD, FACC, FASPC,Michael Koren, MD, FACC ,Erin D. Michos, MD, MHS,Michael Blaha, MD,Deepak Bhatt, MD, MPH, MBA

May 29th 2024

The panel of medical experts addresses the challenges in raising awareness among healthcare providers about various medications and the need for increased awareness of the REDUCE-IT trial outcomes.

Other Notable Emerging Lipid-Lowering Treatments

ByPam Taub, MD, FACC, FASPC,Michael Koren, MD, FACC ,Erin D. Michos, MD, MHS,Michael Blaha, MD,Deepak Bhatt, MD, MPH, MBA

May 22nd 2024

Erin Michos, MD, highlights several notable emerging lipid-lowering treatments, including bempedoic acid, the ANGPTL3 inhibitor evinacumab, the MTP inhibitor lomitapide, the ApoB-100 inhibitor mipomersen, and the ApoC-III degradation molecules volanesorsen and olezarsen.

Examining Results from VICTORION-INITIATE Trial

ByPam Taub, MD, FACC, FASPC,Michael Koren, MD, FACC ,Erin D. Michos, MD, MHS,Michael Blaha, MD,Deepak Bhatt, MD, MPH, MBA

May 22nd 2024

Michael Koren, MD, discusses the recently released results from the VICTORIAN-INITIATE (V-INITIATE) trial, which were presented at the 2024 American College of Cardiology (ACC) Annual Scientific Session in Atlanta.

Evaluating Safety of Novel LDL Management Mechanism

ByPam Taub, MD, FACC, FASPC,Michael Koren, MD, FACC ,Erin D. Michos, MD, MHS,Michael Blaha, MD,Deepak Bhatt, MD, MPH, MBA

May 15th 2024

Deepak Bhatt, MD, MPH, MBA, reviews the efficacy and safety data of inclisiran, highlighting its long-term effects and noting that injection site reactions are among the most prominent adverse reactions associated with this medication.

Optimizing PCSK9 Inhibitors and Analyzing Plaque Reduction Data

ByPam Taub, MD, FACC, FASPC,Michael Koren, MD, FACC ,Erin D. Michos, MD, MHS,Michael Blaha, MD,Deepak Bhatt, MD, MPH, MBA

May 15th 2024

Michael Blaha, MD, discusses the efficacy and safety of novel targeted therapies for lowering LDL cholesterol and emphasizes the importance of long-term data in building patient confidence in this new treatment option.

Innovations in Small Interfering RNA (siRNA) Therapy

ByPam Taub, MD, FACC, FASPC,Michael Koren, MD, FACC ,Erin D. Michos, MD, MHS,Michael Blaha, MD,Deepak Bhatt, MD, MPH, MBA

May 8th 2024

Leading experts highlight the established role of PCSK9 inhibitors, such as evolocumab and alirocumab, and introduce the promising second-generation PCSK9 inhibitors, known as small interfering RNA (siRNA), which represent an innovative therapeutic approach that selectively reduces the production of specific proteins through RNA interference.

Ongoing Lp(a) Trials and Clinical Approaches to Treatment

ByPam Taub, MD, FACC, FASPC,Michael Koren, MD, FACC ,Erin D. Michos, MD, MHS,Michael Blaha, MD,Deepak Bhatt, MD, MPH, MBA

May 8th 2024

Panelists discuss ongoing clinical trials aimed at lowering Lipoprotein(a) levels, emphasizing the importance of proactive patient testing, and referring to new guidelines recommending that everyone be tested once in their lifetime.

Stricter LDL-C Targets: Explaining Goalpost Changes to Patients

ByPam Taub, MD, FACC, FASPC,Michael Koren, MD, FACC ,Erin D. Michos, MD, MHS,Michael Blaha, MD,Deepak Bhatt, MD, MPH, MBA

May 1st 2024

Key opinion leaders in cardiology share insights on reducing LDL cholesterol to manage cardiovascular disease risk, educating patients not reaching goals, and implementing real-world clinical strategies for maintaining lower LDL levels.

Overview of Low-Density Lipoprotein Cholesterol Management

ByPam Taub, MD, FACC, FASPC,Michael Koren, MD, FACC ,Erin D. Michos, MD, MHS,Michael Blaha, MD,Deepak Bhatt, MD, MPH, MBA

May 1st 2024

Erin Michos, MD, delivers a comprehensive review of lipid management and its influence on cardiovascular disease, emphasizing recent studies that underscore the need for improved treatment strategies for high-risk patients.

Clinical Pearls on Lipid Management

ByKeith C. Ferdinand, MD, FACC, FAHA, FASH, FNLA,Erin D. Michos, MD, MHS,Christie Ballantyne, MD,Mary McGowan, MD, FNLA,Payal Kohli, MD, FACC

November 27th 2023

A panel of expert cardiologists share their clinical pearls for managing patients with hyperlipidemia.

Novel Targets for Lipid Level Lowering and Implementation of Lipid Therapy

ByKeith C. Ferdinand, MD, FACC, FAHA, FASH, FNLA,Erin D. Michos, MD, MHS,Christie Ballantyne, MD,Mary McGowan, MD, FNLA,Payal Kohli, MD, FACC

November 27th 2023

Medical experts discuss the importance of screening for Lp(a) and ongoing trials targeting this protein. Moreover, other new targets for the treatment of hyperlipidemia are reviewed.

The Role of Lipoprotein A in Lipid Lowering

ByKeith C. Ferdinand, MD, FACC, FAHA, FASH, FNLA,Erin D. Michos, MD, MHS,Christie Ballantyne, MD,Mary McGowan, MD, FNLA,Payal Kohli, MD, FACC

November 27th 2023

Drs Michos, McGowan, and Kohli discuss Lp(a) and the development of cardiovascular disease.

Long-term efficacy and safety of PCSK9 inhibitors

ByKeith C. Ferdinand, MD, FACC, FAHA, FASH, FNLA,Erin D. Michos, MD, MHS,Christie Ballantyne, MD,Mary McGowan, MD, FNLA,Payal Kohli, MD, FACC

November 27th 2023

Drs Kohli and McGowan review recently published long-term efficacy and safety data on the use of a PCSK9-inhibitor.

Starting Combination Therapy Early

ByKeith C. Ferdinand, MD, FACC, FAHA, FASH, FNLA,Erin D. Michos, MD, MHS,Christie Ballantyne, MD,Mary McGowan, MD, FNLA,Payal Kohli, MD, FACC

October 5th 2023

The panelists discuss how and when to use combination therapy in patients with hyperlipidemia.

Nonstatin Lipid-Lowering Agents

ByKeith C. Ferdinand, MD, FACC, FAHA, FASH, FNLA,Erin D. Michos, MD, MHS,Christie Ballantyne, MD,Mary McGowan, MD, FNLA,Payal Kohli, MD, FACC

October 5th 2023

Dr Michos discusses safety and efficacy of available nonstatin therapies and emerging agents for treating hyperlipidemia.

Statin Intolerance

ByKeith C. Ferdinand, MD, FACC, FAHA, FASH, FNLA,Erin D. Michos, MD, MHS,Christie Ballantyne, MD,Mary McGowan, MD, FNLA,Payal Kohli, MD, FACC

September 28th 2023

Cardiologists discuss managing statin intolerance in clinical practice, highlighting the importance of creating individualized plans and when to initiate nonstatin therapies.